

AD 665412

# EFFECT OF AZATHIOPRINE AND AMETHOPTERIN ON SECONDARY DISEASE IN THE RHESUS MONKEY

JAMES R. ELTRINGHAM, Captain, USAF, MC

DONALD R. ANDERSON, Ph.D.

ROY L. DEHART, Major, USAF, MC

September 1967

AD 665412  
FEB 23 1968  
A

This copy is for public use  
distribution is unlimited

USAF School of Aerospace Medicine  
Aerospace Medical Division (AFSC)  
Brooks Air Force Base, Texas

Best Available Copy

Qualified requesters may obtain copies of this report from DDC. Orders will be expedited if placed through the librarian or other person designated to request documents from DDC.

When U. S. Government drawings, specifications, or other data are used for any purpose other than a definitely related government procurement operation, the government thereby incurs no responsibility nor any obligation whatsoever; and the fact that the government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

This document has been approved for public release and sale; its distribution is unlimited.

SECRET	WHILE PENDING
CONFIDENTIAL	TOP SECRET
NO FORN DISSEM	
BY	DISTRIBUTION CONTROL
DISC.	ANNUAL AND SPECIAL

**EFFECT OF AZATHIOPRINE AND AMETHOPTERIN ON SECONDARY DISEASE  
IN THE RHESUS MONKEY**

**JAMES R. ELTRINGHAM, Captain, USAF, MC**

**DONALD R. ANDERSON, Ph.D.**

**ROY L. DEHART, Major, USAF, MC**

## FOREWORD

The work described in this paper was accomplished in the Radiobiology Branch under task No. 776703. The work was performed from November 1965 through March 1966. The paper was submitted for publication on 19 July 1967.

The experiments reported herein were conducted according to the "Principles of Laboratory Animal Care" of the National Society for Medical Research.

Azathioprine was obtained from Burroughs Wellcome and Co., Inc., Tuckahoe, N.Y. The ICD analyses utilized a commercially available kit, Dermatube-ICD, Worthington Biochemical Corp., Freehold, N.J. SGPT analyses are currently performed using a commercially available kit from Dade Reagents, Inc., Miami, Fla. Protein electrophoresis was performed using a Beckman Microzone Electrophoresis System, Beckman Instruments, Inc., Fullerton, Calif.

The authors thank Dr. P. Crump and R. McNee of the Biometrics Branch for statistical support; Major H. Casey and Captain J. Woodruff for interpretation of the histologic sections; Staff Sergeant B. Kennon and Airman First Class H. Samuels of the Veterinary Sciences Division for technical support; and Airman First Class G. Ford for his assistance in many aspects of this project.

This report has been reviewed and is approved.



GEORGE E. SCHAFER  
Colonel, USAF, MC  
Commander

## ABSTRACT

Forty-five rhesus monkeys received 900 R whole-body irradiation from a cobalt-60 source followed by allogeneic bone marrow transplants. The animals were randomly divided into three groups: (1) bone marrow, no drug; (2) bone marrow, azathioprine; and (3) bone marrow, amethopterin. Supportive care was the same for all groups. Although there was a statistically significant prolongation of the average survival time in the group receiving amethopterin, the net effect was one of briefly delaying the onset of secondary disease as the clinical course of these animals ultimately paralleled that of the other groups. There was no significant difference in the average survival time of the azathioprine group as compared with the control group, and by the criteria cited there were fewer takes effected in the animals receiving azathioprine. The two drugs tested were essentially ineffective in the dose levels and regimens utilized.

## EFFECT OF AZATHIOPRINE AND AMETHOPTERIN ON SECONDARY DISEASE IN THE RHEBUS MONKEY

### I. INTRODUCTION

Considerable species variation exists in the course of secondary disease after postirradiation allogeneic bone marrow transplantation. In mice late mortality may range up to 100%, and in dogs a clinically severe syndrome has been described by Thomas et al. (22, 23) and Cole and Alpen (7). Other species have been shown to manifest secondary disease, and the species differences have been summarized by Van Putten (21). In primates successful postirradiation allogeneic bone marrow transplantation is followed by the rapid onset of a severe and uniformly fatal form of secondary disease. The clinical syndrome and pertinent pathologic findings have been well documented in the rhesus monkey (8, 9, 10). The similarity between the course of secondary disease in the monkey and man provides a potentially useful model to evaluate the ability of various immunosuppressive agents to modify secondary disease in humans (5).

Uphoff (26) in 1958 showed that amethopterin was effective in altering the course of secondary disease in mice; this finding was later confirmed by Lochte et al. (14). Thomas and his associates (23, 24, 25) have shown that in dogs receiving allogeneic bone marrow transplants it is possible to increase the survival time by treatment with amethopterin. Treatment regimens included administration of amethopterin both pre- and posttransplantation. There is limited information available in the literature on the effect of immunosuppressive agents on the course of secondary disease in the rhesus monkey. Van Putten (21) in 1964 reported preliminary results using amethopterin and azathioprine and suggested

that the drugs might prove useful. Since the completion of this study, more information has become available. Muller-Berat et al. (19) and Van Bekkum (5) have reported some success in modifying secondary disease in monkeys by use of amethopterin and cyclophosphamide, with a greater degree of success using the latter drug.

The ability of azathioprine to suppress immune responses in humans after organ transplants and the effectiveness of amethopterin in attenuating secondary disease in rodents and dogs prompted a trial of these drugs in the rhesus monkey.

### II. MATERIALS AND METHODS

Forty-five rhesus monkeys (27 males and 18 females), weighing 2.4 to 3.5 kg., were divided into 15 sets of 3 animals each. In each set the animals were of similar weights and identical sex and red cell type. Erythrocytic typing in the rhesus monkey has been previously described by Owen and Anderson (20). Animals within each set were randomly assigned to one of the two drug groups or the control group. The animals were used as both donors and recipients, and animals within each set were randomly matched for this purpose.

The animals were lightly anesthetized with intravenous sodium thiopental; both buttocks and thighs were shaved and prepared for surgery, and a stab wound was made over the greater trochanter of one of the femura. A hole was drilled through the trochanteric fossa using a Steinmann pin ( $\frac{3}{16}$  or  $\frac{1}{8}$  inch) in a hand chuck. This route of obtaining bone

marrow specimens from the rhesus monkey has been described by several authors (1, 12). A Vim-Silverman needle (3¼ inches) was inserted into the marrow cavity and the marrow aspirated by advancing and retracting the needle several times along the length of the marrow cavity. The needle was connected to a vacuum source through a three-way stopcock, which allowed the marrow to be intermittently mixed with heparinized TC-199 medium (Difco) during aspiration. After the marrow was obtained from one femur, the animal was turned and the procedure repeated on the opposite side. This technic is relatively simple, and it is possible to aspirate the marrow from the femurs of 8 monkeys in 1½ to 2 hours. By use of this method, the transplants were performed four days a week for a period of two weeks.

The vacuum apparatus is shown in figure 1. The vacuum pump was connected to a tank, which served to dampen any marked pressure changes within the system; the pressure was held at approximately ½ atmosphere. A bleeder valve allowed the pressure to be increased

above the minimum obtained with the pump alone, if desired. A sidearm flask served as a trap to exclude any fluid accidentally aspirated beyond the plastic tube used for marrow collection. The plastic tube was removed when partially filled; additional media were added; then the tube was capped with a perforated top and stored in ice. Connections between the pump, tank, and other points within the system were made with Tygon tubing.

After aspiration, the marrow was mixed with an additional 30 ml. of TC-199 medium to a final volume of approximately 90 ml. Heparin (10,000 U.S.P. units), 32,000 units of penicillin, and 40 mg. of streptomycin were added to each liter of TC-199 medium. The aspirated marrow mixture was stored in ice until centrifugation, which was performed in a refrigerated centrifuge (2° to 4° C.) for 20 minutes at 170 × g. The majority of the supernatant fluid and fat was aspirated and the marrow resuspended by aspiration into a syringe through a 20-gage needle, which also served to remove any small clots and bone chips. No other filtration or screening was utilized. The




FIGURE 1

*Vacuum apparatus used for marrow extractions.*

final marrow suspension constituted a volume of 20 to 30 ml. and was stored at 2° to 4° C. until reinfusion, a period of 2 to 3 hours. Total storage time for the aspirated marrow was 4 to 6 hours.

After a 2- to 3-hour recovery from anesthesia, the animals were irradiated using a cobalt-60 facility, the details of which have been previously described (13). The animals were irradiated in a wooden box using anterior and posterior fields; they were turned halfway through the period of irradiation, thus requiring a 1- to 2-minute interruption. A midline air dose of 980 R was delivered at 98 R per minute. Approximately 1 to 2 hours post-irradiation the animals were again lightly anesthetized with intravenous sodium thiopental, and marrow from the appropriate donor was infused in a leg vein. The marrow was injected over a period of 1 minute. There was no direct morbidity or mortality associated with the transplantation procedure. Prophylactic antibiotics were administered daily from days 2 to 15 posttransplantation and consisted of 300,000 units of penicillin and 40 mg. of tetracycline intramuscularly once a day. Preliminary work using this transplantation procedure in animals receiving autologous transplants after a midline air dose of 930 or 980 R under similar conditions resulted in takes in all 14 animals. Two animals subsequently died at 28 and 37 days; both deaths may have been secondary to drugs which the animals were receiving, as the peripheral blood counts had returned to normal before the animals died. The remaining 12 animals are alive 19 months after transplantation.

Since the marrow was obtained from living donors, the suspensions consisted of a mixture of bone marrow and blood and the cell counts have been expressed as "total nucleated cells." The number of cells received ranged from  $4.1 \times 10^8$  to  $2.2 \times 10^9$  total nucleated cells ( $1.2 \times 10^8$  to  $6.7 \times 10^8$  nucleated cells per kilogram). Those animals receiving immunosuppressive agents were given the initial dose at the time of the marrow infusion (day 0). Azathioprine (3 mg./ml.) was administered intravenously in a dose of 3.0 mg./kg. on days

0, 1, and 2, and 1.0 mg./kg. on days 3 through 14 posttransplantation. Amethopterin (5 mg./ml.) was administered in four subcutaneous sites each day on days 0, 2, 4, 6, and 8 posttransplantation in a dose of 1.0 mg./kg. A summary of pertinent transplantation data for each animal is presented in table I.

All animals were housed in individual, adjacent wire cages with free access to water. Routine feeding consisted of a commercial monkey chow interspersed with peanuts and fruit. Daily weights and temperatures were obtained on each animal as well as evaluation of activity, appetite, appearance, and elimination. If an animal was found dead in the morning, survival was scored until the preceding day. All animals were necropsied, and the histopathologic findings will be reported separately.

Baseline blood samples were obtained on two occasions in the six weeks before transplantation; the second sample was obtained approximately two weeks before transplantation and has been presented in the following data as the baseline value. Posttransplantation, the animals were sampled twice weekly for peripheral blood counts and once per week for serum enzyme and chemistry determinations. The initial sample was obtained on day 7 with subsequent samples on day 10 or 11 (these points have been pooled in the data and presented as an 11-day point), day 14, and in the few survivors, on days 17 and 21. In addition, counts were occasionally performed if an animal was extremely ill or moribund to determine if there had been a take. Since most of the postirradiation data does not follow a normal distribution, the data have been calculated and tabulated as the 25th, 50th, and 75th percentiles.

The peripheral blood counts included hematocrit, platelet, reticulocyte, and leukocyte counts; serum chemistry and enzyme determinations included isocitric dehydrogenase (ICD), serum glutamic pyruvic transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase, lactic dehydrogenase, leucine aminopeptidase (LAP),

TABLE I  
Summary of transplantation data

Host and red cell type	Group	Total cells received	Number of cells/kg.	Take	Survival (days)
1 ABF	Control	$1.9 \times 10^8$	$6.6 \times 10^4$	Yes	12
	Amethopterin	$8.9 \times 10^8$	$3.0 \times 10^4$	Yes	21
	Azathioprine	$5.2 \times 10^8$	$1.7 \times 10^4$	No	8
2 ABCF	Control	$1.0 \times 10^8$	$3.6 \times 10^4$	No	9
	Amethopterin	$9.8 \times 10^8$	$3.4 \times 10^4$	Yes	15
	Azathioprine	$1.0 \times 10^8$	$3.6 \times 10^4$	No	8
3 BDF	Control	$5.5 \times 10^8$	$2.1 \times 10^4$	No	6
	Amethopterin	$1.2 \times 10^9$	$3.9 \times 10^4$	Yes	17
	Azathioprine	$1.5 \times 10^9$	$4.7 \times 10^4$	Yes	11
4 BDF	Control	$8.1 \times 10^8$	$2.8 \times 10^4$	No	7
	Amethopterin	$5.7 \times 10^8$	$1.8 \times 10^4$	Yes	19
	Azathioprine	$8.0 \times 10^8$	$3.3 \times 10^4$	Yes	10
5 BCF	Control	$4.5 \times 10^8$	$1.7 \times 10^4$	Yes	8
	Amethopterin	$6.0 \times 10^8$	$2.3 \times 10^4$	Yes	17
	Azathioprine	$5.4 \times 10^8$	$2.1 \times 10^4$	No	14
6 BCF	Control	$2.2 \times 10^8$	$6.7 \times 10^4$	Yes	8
	Amethopterin	$1.3 \times 10^9$	$4.1 \times 10^4$	Yes	14
	Azathioprine	$1.8 \times 10^9$	$5.1 \times 10^4$	Yes	11
7 BF	Control	$8.4 \times 10^8$	$3.0 \times 10^4$	Yes	12
	Amethopterin	$8.4 \times 10^8$	$2.7 \times 10^4$	No	7
	Azathioprine	$1.5 \times 10^9$	$4.5 \times 10^4$	Yes	13
8 BF	Control	$1.6 \times 10^9$	$6.4 \times 10^4$	Yes	13
	Amethopterin	$1.1 \times 10^9$	$3.9 \times 10^4$	Yes	15
	Azathioprine	$1.4 \times 10^9$	$5.4 \times 10^4$	Yes	12
9 BEF	Control	$1.0 \times 10^8$	$3.4 \times 10^4$	Yes	14
	Amethopterin	$1.5 \times 10^9$	$6.3 \times 10^4$	Yes	15
	Azathioprine	$6.1 \times 10^8$	$2.2 \times 10^4$	No	8
10 BEF	Control	$1.4 \times 10^9$	$4.2 \times 10^4$	Yes	13
	Amethopterin	$1.3 \times 10^9$	$4.1 \times 10^4$	Yes	15
	Azathioprine	$1.1 \times 10^9$	$4.1 \times 10^4$	No	9
11 BF	Control	$5.0 \times 10^8$	$1.7 \times 10^4$	Yes	11
	Amethopterin	$9.7 \times 10^8$	$3.1 \times 10^4$	Yes	15
	Azathioprine	$9.1 \times 10^8$	$2.8 \times 10^4$	No	13
12 BF	Control	$1.0 \times 10^9$	$3.3 \times 10^4$	Yes	13
	Amethopterin	$8.0 \times 10^8$	$2.9 \times 10^4$	No	12
	Azathioprine	$5.8 \times 10^8$	$2.0 \times 10^4$	Yes	10
13 BF	Control	$4.1 \times 10^8$	$1.2 \times 10^4$	No	8
	Amethopterin	$1.1 \times 10^9$	$3.1 \times 10^4$	No	9
	Azathioprine	$1.2 \times 10^9$	$4.1 \times 10^4$	No	8
14 BCF	Control	$9.2 \times 10^8$	$3.3 \times 10^4$	Yes	12
	Amethopterin	$1.5 \times 10^9$	$4.7 \times 10^4$	No	13
	Azathioprine	$4.4 \times 10^8$	$1.4 \times 10^4$	No	7
15 BF	Control	$1.1 \times 10^9$	$4.2 \times 10^4$	Yes	11
	Amethopterin	$1.0 \times 10^9$	$3.6 \times 10^4$	Yes	17
	Azathioprine	$1.2 \times 10^9$	$4.8 \times 10^4$	Yes	12

blood urea nitrogen (BUN), creatinine, and total protein with electrophoresis. The methods of determination and normal values for the rhesus monkey in our laboratory have been previously reported by Anderson (3) with the exception of the isocitric dehydrogenase.

### III. RESULTS AND DISCUSSION

Several authors have demonstrated the ability of transplanted allogeneic bone marrow to proliferate in lethally irradiated monkeys (1, 15, 19, 27, 28). In earlier work from our laboratory, the erythrocytic types in donor and recipient animals were purposely mismatched in order to confirm that a take had been established (27, 28). In the present study, since each set was of the same erythrocytic type, it was not possible to use this method of assessing a take. In addition, since the animals in each set were of the same sex, it was not possible to evaluate the presence of female donor cells in males by karyotype or by using dramatic markers as described by Magliulo et al. (15). We therefore defined a take as an increasing reticulocyte count ( $\geq 0.3\%$ ) or an increasing leukocyte count ( $\geq 1,000$  cells) per cubic millimeter, or both. Justification for this was based on the results obtained from two preliminary groups of animals in which: (1) animals receiving autologous transplants under the above conditions showed beginning recovery of their peripheral blood elements by 10 days posttransplantation; and (2) 10 animals irradiated under the above conditions but

not receiving bone marrow transplants showed no evidence of recovery of either reticulocyte or leukocyte counts before death, which occurred from 10 to 16 days postirradiation, with a median of 12 days. Pertinent data from this group have been included for purposes of comparison.

By use of these criteria to define a take, there were 73% takes in both the control and amethopterin groups and 47% in the azathioprine group (table II). These numbers probably represent minimal figures, as some animals died before the time that a take was evident from the peripheral blood counts.

The hematologic data for all groups have been tabulated in table III. The hematocrits declined in all groups postirradiation, as shown in figure 2. The leukocyte and reticulocyte counts (fig. 3) were markedly reduced at day 7, as were the platelet counts (fig. 2), although the group receiving no bone marrow showed a less marked platelet drop at 7 days, thus raising the possibility that the graft-versus-host reaction in the animals receiving allogeneic bone marrow transplants contributed to platelet destruction. The group receiving only bone marrow showed an increase in the leukocyte, platelet, and reticulocyte counts at day 11. The azathioprine group showed a similar increase in platelets by day 11, but no change in the leukocyte count at that time; the reticulocyte count was also increasing at day 11, but not as

TABLE II  
Percent takes

Group*	Reticulocytes $\geq 0.3\%$		WBC $\geq 1,000/\text{mm}^3$		Total takes	
	Number	Percent	Number	Percent	Number	Percent
Control	9	60	11	73	11	73
Azathioprine	7	47	1	6	7	47
Amethopterin	11	73	8	53	11	73

\*Fifteen animals in each group.

FIGURE 2

Variation of hematocrit and platelet count after transplantation.

TABLE III

Hematocrit, platelets, leukocytes, reticulocytes tabulated in percentiles: 50th (25th, 75th)


Day	Irradiation only	Bone marrow, no drug	Bone marrow, azathioprine	Bone marrow, amethopterin
Hematocrit (%)				
Baseline	40.5 (39.0, 42.5)	39.0 (37.0, 41.0)	37.0 (35.0, 39.0)	38.0 (37.0, 40.0)
7	37.5 (36.0, 39.5)	35.0 (33.0, 38.0)	34.0 (32.0, 37.0)	37.0 (33.0, 39.0)
11	34.5 (26.5, 37.5)	33.0 (28.0, 38.0)	29.0 (24.0, 34.0)	33.5 (31.0, 34.0)
14	—	—	—	31.0 (28.0, 32.5)
Platelets $\times 10^3$				
Baseline	344 (309, 368)	276 (236, 291)	265 (236, 352)	267 (248, 275)
7	186 (133, 205)	26 (17, 62)	70 (14, 58)	50 (40, 102)
11	22 (11, 29)	77 (60, 89)	65 (37, 80)	52 (24, 58)
14	—	—	—	98 (60, 136)
Leukocytes $\times 10^3$				
Baseline	12.3 (11.5, 13.9)	9.20 (6.25, 10.9)	8.85 (6.60, 10.9)	7.20 (5.90, 8.45)
7	0.28 (0.22, 0.40)	0.45 (0.25, 0.65)	0.35 (0.15, 0.55)	0.10 (0.05, 0.20)
11	0.11 (0.05, 0.17)	2.00 (1.00, 2.30)	0.40 (0.23, 0.73)	0.25 (0.15, 0.40)
14	—	—	—	1.06 (0.63, 1.59)
Reticulocytes (%)				
Baseline	0.5 (0.4, 0.5)	0.7 (0.4, 0.9)	0.5 (0.3, 0.7)	0.5 (0.3, 1.1)
7	0	0	0	0
11	0	1.0 (0.6, 2.4)	0.4 (0.05, 1.00)	0.1 (0, 0.2)
14	—	—	—	0.5 (0.4, 2.5)

FIGURE 3

Variation of leukocyte and reticulocyte counts after transplantation.

**KEY:**

- B = BASELINE
- = IRRADIATION ONLY
- = BONE MARROW, CONTROL
- ▲ = BONE MARROW, AZATHIOPRINE
- △ = BONE MARROW, AMETHOPTERIN



**KEY:**

- B = BASELINE
- = IRRADIATION ONLY
- = BONE MARROW, CONTROL
- ▲ = BONE MARROW, AZATHIOPRINE
- △ = BONE MARROW, AMETHOPTERIN




TABLE IV

*ICD, SGOT, SGPT, and LDH tabulated in percentiles: 50th (25th, 75th)*

Day	Irradiation only	Bone marrow, no drug	Bone marrow, azathioprine	Bone marrow, amethopterin
<b>ICD</b>				
Baseline	10 (6, 17)	14 (10, 21)	14 (11, 19)	18 (10, 17)
7	11 (9, 14)	54 (31, 64)	60 (36, 89)	17 (13, 24)
14	—	—	—	41 (24, 62)
<b>SGOT</b>				
Baseline	36 (29, 40)	26 (18, 33)	23 (22, 32)	25 (20, 28)
7	23 (21, 26)	65 (32, 115)	76 (53, 97)	51 (42, 64)
14	—	—	—	50 (43, 96)
<b>SGPT</b>				
Baseline	19 (19, 22)	27 (21, 30)	25 (23, 30)	22 (20, 31)
7	27 (23, 29)	66 (42, 91)	76 (55, 105)	52 (32, 74)
14	—	—	—	64 (41, 96)
<b>LDH</b>				
Baseline	555 (390, 680)	415 (360, 510)	395 (320, 565)	430 (340, 465)
7	448 (385, 485)	1,088 (715, 1,338)	1,145 (840, 1,395)	815 (550, 950)
14	—	—	—	653 (565, 1,060)

TABLE V

*Leucine aminopeptidase (LAP), alkaline phosphatase, BUN, and creatinine tabulated in percentiles: 50th (25th, 75th)*

Day	Irradiation only	Bone marrow, no drug	Bone marrow, azathioprine	Bone marrow, amethopterin
<b>LAP</b>				
Baseline	190 (159, 209)	175 (147, 217)	177 (149, 221)	231 (173, 259)
7	171 (133, 185)	305 (169, 357)	250 (165, 412)	170 (153, 257)
14	—	—	—	113 (90, 226)
<b>Alkaline phosphatase</b>				
Baseline	19 (16, 21)	14 (11, 17)	15 (12, 22)	15 (12, 19)
7	13 (11, 19)	7 (6, 9)	10 (6, 12)	8 (6, 11)
14	—	—	—	9 (6, 11)
<b>BUN (mg %)</b>				
Baseline	19 (17, 21)	18 (16, 20)	19 (17, 20)	19 (17, 21)
7	21 (18, 34)	45 (34, 55)	45 (30, 95)	38 (23, 59)
14	—	—	—	33 (22, 45)
<b>Creatinine (mg. %)</b>				
Baseline	0.9 (0.8, 1.0)	0.9 (0.8, 1.0)	0.9 (0.8, 1.0)	0.9 (0.8, 1.0)
7	0.9 (0.7, 1.0)	1.0 (0.9, 1.1)	0.9 (0.7, 1.4)	0.8 (0.7, 0.9)
14	—	—	—	0.8 (0.5, 0.9)

sharply as in the group receiving no immunosuppressive agents. The group receiving amethopterin manifested a sustained suppression of the leukocyte and platelet counts at day 11; however, the counts increased by day 14; the reticulocyte counts showed a slight increase by day 11 and a further increase by day 14. The reticulocyte counts of all of the groups receiving transplants were increasing by day 11, showing the most marked increase in the group receiving no immunosuppressive agents. The reticulocyte, leukocyte, and platelet counts increased during the period of increasing mortality for each of the groups receiving bone marrow transplants.

The serum chemistry and enzyme determinations have been tabulated in tables IV, V, and VI, and the more significant results are shown in figure 4. The isocitric dehydrogenase (ICD) remained essentially unchanged at 7 days in the group receiving no bone marrow and in the amethopterin group. The control group and the azathioprine group showed a sharp and significant increase in this parameter at 7 days ( $P < .01$ ). The SGOT and SGPT show parallel trends, but differ from the ICD determination at 7 days as there is a significant elevation in all of the groups receiving bone marrow transplants, while in the group receiving no bone marrow there is not a

TABLE VI  
Total protein and electrophoresis results tabulated in percentiles: 50th (25th, 75th)

Day	Irradiation only	Bone marrow, no drug	Bone marrow, azathioprine	Bone marrow, amethopterin
Total protein (gm. %)				
Baseline	7.6 (7.2, 8.0)	7.7 (7.3, 8.2)	8.1 (6.9, 8.3)	7.7 (7.4, 8.1)
7	6.9 (6.6, 7.1)	6.3 (5.9, 6.8)	6.3 (5.6, 6.6)	7.1 (6.8, 7.5)
14	—	—	—	5.8 (5.6, 6.2)
Albumin (gm. %)				
Baseline	4.6 (4.4, 4.8)	4.5 (4.0, 4.8)	4.4 (4.2, 4.7)	4.9 (4.2, 5.1)
7	4.6 (4.4, 4.7)	3.1 (2.8, 3.5)	3.0 (2.8, 3.3)	3.7 (3.0, 4.2)
14	—	—	—	2.8 (2.3, 3.6)
Alpha <sub>1</sub> and alpha <sub>2</sub> globulins (gm. %)				
Baseline	0.3 (0.3, 0.4)	0.9 (0.8, 1.1)	0.9 (0.8, 1.1)	0.8 (0.7, 1.0)
7	0.6 (0.5, 0.6)	1.0 (0.8, 1.4)	1.1 (0.9, 1.5)	1.1 (0.9, 1.2)
14	—	—	—	0.9 (0.7, 1.3)
Beta globulins (gm. %)				
Baseline	1.2 (0.9, 1.3)	1.3 (0.9, 1.5)	1.2 (1.0, 1.3)	1.0 (0.9, 1.3)
7	1.1 (0.9, 1.2)	1.3 (1.2, 1.6)	1.4 (1.3, 1.5)	1.5 (1.0, 1.7)
14	—	—	—	1.2 (1.1, 1.6)
Gamma globulins (gm. %)				
Baseline	1.5 (1.3, 1.6)	1.0 (0.9, 1.2)	1.3 (0.8, 1.6)	1.1 (0.9, 1.3)
7	0.8 (0.6, 0.9)	0.7 (0.5, 0.8)	0.8 (0.5, 0.8)	0.8 (0.7, 1.0)
14	—	—	—	0.6 (0.3, 0.7)

KEY:

- B = BASELINE
- = IRRADIATION ONLY
- ◻ = BONE MARROW, CONTROL
- ▲ = BONE MARROW, AZATHIOPRINE
- △ = BONE MARROW, AMETHOPTERIN




FIGURE 4

Variation of ICD, SGOT, and SGPT after transplantation.

significant difference between the baseline value and the 7-day value. This sharp increase in the SGOT, SGPT, and the ICD at 7 days is not seen in animals receiving autologous transplants (11, 27). The ICD level is reported to be a sensitive measure for the determination of hepatic cell injury (2). In this study the group receiving amethopterin revealed no significant change in the ICD level at 7 days, while the SGOT and SGPT levels were elevated significantly ( $P < .01$ ). At 14 days the ICD level increased ( $P < .05$ ), while there was no significant change in the SGOT and SGPT levels as compared to the 7-day determinations.

Since the objective of the study was to maintain living animals either in the form of stable chimeras or as possible reversals, the parameter of greatest interest was survival. Examination of the survival curves (fig. 5) shows no significant difference between the curves for the control and azathioprine groups, with no survivors beyond 14 days. Two-thirds of the group treated with amethopterin were alive at day 14, but there were no survivors beyond 21 days.

A more meaningful comparison is that of the average survival time, which was 10.5 days




FIGURE 5

*Survival after transplantation for the three experimental groups.*

in the control group, 10.3 days in the azathioprine group, and 14.7 days in the amethopterin group. There is no significant difference between the average survival times of the control and azathioprine groups; however, the net effect of the amethopterin appeared to be simply one of forestalling the onset of secondary disease as the clinical course of this group paralleled the others after a brief delay. The survival times for the different blood types showed no statistically significant relationship with red cell types. In addition, an analysis of the number of cells received showed no significant difference among the treatment group means, indicating no bias in the survival times due to differences in the number of cells received. Comparison of the average survival times of the control and amethopterin groups yields  $P < .001$ .

Figure 6 shows the estimated degree of cellularity of vertebral bone marrow sections obtained at necropsy versus the day of death.

Cellularity of vertebral marrow for normal monkeys in this age group in our colony is approximately 65% to 70%. Differing symbols have been used to indicate whether a take was obtained as defined by the peripheral blood findings. The control and amethopterin groups show similar pictures, with the latter shifted slightly in time corresponding to the increased survival times. The azathioprine group shows a marked reduction in cellularity as compared with the other groups. This finding was not unexpected since animals receiving autologous transplants with this azathioprine regimen showed evidence of marked bone marrow depression until administration of the drug was discontinued. Vertebral marrow sections of the 10 animals which did not receive marrow transplants appeared hemorrhagic or had less than 5% cellularity.

While the dose of radiation used in the present study is supralethal for animals in




FIGURE 6  
*Relationship between vertebral marrow cellularity and day of death.*

our colony, there were no early deaths in the nontransplanted group or in the animals treated with autologous bone marrow, suggesting that the dose used is below that which will cause a significant number of early deaths from gastrointestinal damage. An examination of the number of deaths occurring each day posttransplantation (fig. 7) shows that there were several early deaths in the control and azathioprine groups. Few deaths occurred during this period in the amethopterin group.

The number of animals is small, but the question may be raised as to whether the early deaths are the result of severe secondary disease or additional stress from rejection of

the graft superimposed on the radiation damage. Crouch and Overman (9) have suggested that the decreased incidence of takes in their lethally irradiated, lower-dose groups may be due to rejection of the transplant by the host. In the present study this may be the mechanism for some of the early deaths in spite of a supralethal dose of radiation. If this were true, one might speculate that the potential action of an immunosuppressive agent is twofold: (1) suppression of the host's residual immune mechanisms with an overall increase in the number of takes; and (2) suppression of the graft-versus-host reaction. In the present study there was no evidence of an increased number of takes with the dose regimens utilized.




FIGURE 7

Number of deaths per day for the three experimental groups.

Although it is technically feasible to effect successful bone marrow transplants in man and other primates, the fatal secondary disease which intervenes remains an enormous obstacle to practical success. The potential usefulness of allogeneic bone marrow transplants in man—such as in leukemic patients, individuals with disseminated radiosensitive metastases, or victims of radiation accidents—remains a considerable stimulus to finding a successful method of overcoming secondary disease in man. Although Mathe and associates (16) and Bellby et al. (4) have had success in establishing chimerism in man, the overall results to

date have been disappointing. Recently, evidence is accumulating that cyclophosphamide may be of some value in modifying secondary disease in primates (5, 11, 19), and it is possible that more effective immunosuppressive agents will appear in the future. Other possible approaches include antilymphocyte serums, better typing of histocompatibility, the use of pooled marrow (16, 18), or modification of the immunologically competent cells by temporary storage of marrow under various conditions as suggested by Mathe et al. (17) and Van Bekkum (6). Combinations of these approaches may possibly prove effective.

#### REFERENCES

1. Allen, J. R., J. L. van Lancker, and R. C. Wolf. The use of bone marrow transplants in the protection of rhesus monkeys against total body x-irradiation. *Amer. J. Vet. Res.* 25:1740 (1964).
2. Amador, E., and W. E. C. Wacker. Enzymatic methods used for diagnosis. In Glick, D. (ed.). *Methods of biochemical analysis*, vol. 13, pp. 286-287. New York: Interscience Publishers, 1965.
3. Anderson, D. R. Normal values for clinical blood chemistry tests of the *Macaca mulatta* monkey. *Amer. J. Vet. Res.* 27:1484 (1966).
4. Bellby, J. O. W., I. S. Cade, A. M. Jelliffe, D. M. Parkin, and J. W. Stewart. Prolonged survival of bone-marrow graft resulting in a blood-group chimera. *Brit. Med. J.* 1:96 (1960).
5. Van Bekkum, D. W. Present status of bone marrow transplantation following whole body irradiation. *Oncologia (Basel)* 20: supp. 60-72 (1966).
6. Van Bekkum, D. W. The selective elimination of immunologically competent cells from bone marrow and lymphatic cell mixtures. *Transplantation* 2:393 (1964).

7. Cole, L. J., and E. L. Alpen. Homologous bone marrow transplantation in dogs receiving x-radiation plus urethan or 6-mercaptopurine. *Blood* 21:373 (1963).
8. Crouch, B. G., L. M. van Putten, D. W. van Bekkum, and M. J. de Vries. Treatment of total body x-irradiated monkeys with autologous and homologous bone marrow. *J. Nat. Cancer Inst.* 27:53 (1961).
9. Crouch, B. G., and E. R. Overman. Modification of irradiation injury in the monkey by bone marrow transplantation. *Blood* 17:444 (1961).
10. De Vries, M. J., B. G. Crouch, L. M. van Putten, and D. W. van Bekkum. Pathologic changes in irradiated monkeys treated with bone marrow. *J. Nat. Cancer Inst.* 27:67 (1961).
11. Eltringham, J. R. Unpublished data.
12. Hall, A. S., and A. L. Knesevic. Bone marrow sampling in monkeys. *J. Amer. Vet. Med. Ass.* 147:1075 (1965).
13. Hardy, K. A., H. A. W. Spetzler, and R. W. Cochran. The SAM high level cobalt-60 irradiation facility. SAM-TR-65-65, Sept. 1965.
14. Lochte, H. L., A. S. Levy, D. M. Guenther, E. D. Thomas, and J. W. Ferrebee. Prevention of delayed foreign marrow reaction in lethally irradiated mice by early administration of methotrexate. *Nature (London)* 196:1110 (1962).
15. Magliulo, E., B. G. Crouch, and M. J. de Vries. The sex-linked drumstick appendage frequency as a marker for bone marrow transplantation in monkeys. *Blood* 21:620 (1963).
16. Mathe, G., J. L. Amiel, L. Schwarzenberg, A. Cattani, M. Schneider, M. J. de Vries, M. Tubiana, C. Lalanne, J. L. Binet, M. Papiernik, G. Seman, M. Matsukura, A. M. Mery, V. Schwarzmann, and A. Flaisler. Successful allogeneic bone marrow transplantation in man: Chimerism, induced specific tolerance and possible antileukemic effects. *Blood* 25:179 (1965).
17. Mathe, G., J. L. Amiel, L. Schwarzenberg, J. F. Dreke, P. Goldstein, M. Sekiguchi, and J. M. Bechet. Conditioning of immunologically competent cells by incubation at 37° C. *Ann. N.Y. Acad. Sci.* 129:355 (1966).
18. Mathe, G., J. L. Amiel, M. Matsukura, and A. M. Mery. Restoration of haemopoietic function in the irradiated mouse by means of allogeneic bone-marrow grafts from several donors of different strains. *Brit. J. Haemat.* 10:257 (1964).
19. Müller-Herat, C. N., L. M. van Putten, and D. W. van Bekkum. Cytostatic drugs in the treatment of secondary disease following homologous bone marrow transplantation: Extrapolation from the mouse to the primate. *Ann. N.Y. Acad. Sci.* 129:349 (1966).
20. Owen, R. D., and D. R. Anderson. Blood groups in rhesus monkeys. *Ann. N.Y. Acad. Sci.* 97:4 (1962).
21. Van Putten, L. M. Secondary disease in different species and its modification. *La Greffe des cellules hematopoietiques allogenes*, Paris, 7 to 9 Sept. 1964. Editions du Centre National de la Recherche Scientifique, C.N.R.S., p. 323 (1965).
22. Thomas, E. D., C. A. Ashley, H. L. Lochte, A. Jaretzki, O. D. Sahler, and J. W. Ferrebee. Homografts of bone marrow in dogs after lethal total-body radiation. *Blood* 14:720 (1959).
23. Thomas, E. D., J. A. Collins, E. C. Herman, and J. W. Ferrebee. Marrow transplants in lethally irradiated dogs given methotrexate. *Blood* 19:217 (1962).
24. Thomas, E. D., S. Kasakura, J. A. Cavins, and J. W. Ferrebee. Marrow transplants in lethally irradiated dogs: The effect of methotrexate on survival of the host and the homograft. *Transplantation* 1:571 (1963).
25. Thomas, E. D., G. L. Plain, T. C. Graham, and J. W. Ferrebee. Long-term survival of lethally irradiated dogs given homografts of bone marrow. *Blood* 23:488 (1964).
26. Uphoff, D. E. Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow. *Proc. Soc. Exp. Biol. Med.* 99:651 (1958).
27. Whitcomb, W. H., R. J. Young, G. S. Melville, J. A. Pitcock, and D. R. Anderson. Chemical protection of irradiated monkeys in combination with autologous and homologous marrow transfusion. *Radiat. Res.* 29:339 (1966).
28. Young, R. J., W. H. Whitcomb, G. S. Melville, and D. R. Anderson. Transfusion of homologous and autologous bone marrow in primates exposed to 900 R whole-body x-radiation. Bone marrow therapy and protection in irradiated primates, p. 47. Proceedings of a symposium, 15 to 18 Aug. 1962, Radiobiological Institute of the Organization for Health Research T.N.O., Rijswijk (Z.H.) The Netherlands.

Unclassified

Security Classification

DOCUMENT CONTROL DATA - R&D		
<i>(Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified)</i>		
1. ORIGINATING ACTIVITY (Corporate author) USAF School of Aerospace Medicine Aerospace Medical Division (AFSC) Brooks Air Force Base, Texas		6a. REPORT SECURITY CLASSIFICATION Unclassified
		7a. GROUP
2. REPORT TITLE EFFECT OF AZATHIOPRINE AND AMETHOPTERIN ON SECONDARY DISEASE IN THE RHESUS MONKEY		
3. DESCRIPTIVE NOTES (Type of report and inclusive dates) Nov. 1965 - Mar. 1966		
4. AUTHOR(S) (Last name, first name, initials) Eltringham, James R., Captain, USAF, MC Anderson, Donald R. DeHart, Roy L., Major, USAF, MC		
5. REPORT DATE September 1967	7b. TOTAL NO. OF PAGES 14	7c. NO. OF REFS 28
6a. CONTRACT OR GRANT NO.  A. PROJECT NO.  Task No. 775703		8a. ORIGINATOR'S REPORT NUMBER(S)  SAM-TR-67-94
		8b. OTHER REPORT NO(S) (Any other numbers that may be assigned this report)
10. AVAILABILITY/LIMITATION NOTICES This document has been approved for public release and sale; its distribution is unlimited.		
11. SUPPLEMENTARY NOTES		12. SPONSORING MILITARY ACTIVITY USAF School of Aerospace Medicine Aerospace Medical Division (AFSC) Brooks Air Force Base, Texas
13. ABSTRACT  Forty-five rhesus monkeys received 980 R whole-body irradiation from a cobalt-60 source followed by allogenic bone marrow transplants. The animals were randomly divided into three groups: (1) bone marrow, no drug; (2) bone marrow, azathioprine; and (3) bone marrow, amethopterin. Supportive care was the same for all groups. Although there was a statistically significant prolongation of the average survival time in the group receiving amethopterin, the net effect was one of briefly delaying the onset of secondary disease as the clinical course of these animals ultimately paralleled that of the other groups. There was no significant difference in the average survival time of the azathioprine group as compared with the control group, and by the criteria cited there were fewer takes effected in the animals receiving azathioprine. The two drugs tested were essentially ineffective in the dose levels and regimens utilized.		

DD FORM 1473  
1 JAN 64

Unclassified

Security Classification

Unclassified  
Security Classification

14	KEY WORDS	LINK A		LINK B		LINK C	
		ROLE	WT	ROLE	WT	ROLE	WT
	Radiobiology Pharmacology Radiation Primates, rhesus monkeys Immunosuppression Azathioprine Amethopterin Transplantation, bone marrow						

**INSTRUCTIONS**

1. **ORIGINATING ACTIVITY:** Enter the name and address of the contractor, subcontractor, grantee, Department of Defense activity or other organization (corporate author) issuing the report.
- 2a. **REPORT SECURITY CLASSIFICATION:** Enter the overall security classification of the report. Indicate whether "Restricted Data" is included. Marking is to be in accordance with appropriate security regulations.
- 2b. **GROUP:** Automatic downgrading is specified in DoD Directive 5200.10 and Armed Forces Industrial Manual. Enter the group number. Also, when applicable, show that optional markings have been used for Group 3 and Group 4 as authorized.
3. **REPORT TITLE:** Enter the complete report title in all capital letters. Titles in all cases should be unclassified. If a meaningful title cannot be selected without classification, show title classification in all capitals in parentheses immediately following the title.
4. **DESCRIPTIVE NOTES:** If appropriate, enter the type of report, e.g., interim, progress, summary, annual, or final. Give the inclusive dates when a specific reporting period is covered.
5. **AUTHOR(S):** Enter the name(s) of author(s) as shown on or in the report. Enter last name, first name, middle initial. If military, show rank and branch of service. The name of the principal author is an absolute minimum requirement.
6. **REPORT DATE:** Enter the date of the report as day, month, year, or month, year. If more than one date appears on the report, use date of publication.
- 7a. **TOTAL NUMBER OF PAGES:** The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.
- 7b. **NUMBER OF REFERENCES:** Enter the total number of references cited in the report.
- 8a. **CONTRACT OR GRANT NUMBER:** If appropriate, enter the applicable number of the contract or grant under which the report was written.
- 8b, 8c, & 8d. **PROJECT NUMBER:** Enter the appropriate military department identification, such as project number, subproject number, system numbers, task number, etc.
- 9a. **ORIGINATOR'S REPORT NUMBER(S):** Enter the official report number by which the document will be identified and controlled by the originating activity. This number must be unique to this report.
- 9b. **OTHER REPORT NUMBER(S):** If the report has been assigned any other report numbers (either by the originator or by the sponsor), also enter this number(s).
10. **AVAILABILITY/LIMITATION NOTICES:** Enter any limitations on further dissemination of the report, other than those

imposed by security classification, using standard statements such as:

- (1) "Qualified requesters may obtain copies of this report from DDC."
- (2) "Foreign announcement and dissemination of this report by DDC is not authorized."
- (3) "U. S. Government agencies may obtain copies of this report directly from DDC. Other qualified DDC users shall request through \_\_\_\_\_."
- (4) "U. S. military agencies may obtain copies of this report directly from DDC. Other qualified users shall request through \_\_\_\_\_."
- (5) "All distribution of this report is controlled. Qualified DDC users shall request through \_\_\_\_\_."

If the report has been furnished to the Office of Technical Services, Department of Commerce, for sale to the public, indicate this fact and enter the price, if known.

11. **SUPPLEMENTARY NOTES:** Use for additional explanatory notes.

12. **SPONSORING MILITARY ACTIVITY:** Enter the name of the departmental project office or laboratory sponsoring (paying for) the research and development. Include address.

13. **ABSTRACT:** Enter an abstract giving a brief and factual summary of the document indicative of the report, even though it may also appear elsewhere in the body of the technical report. If additional space is required, a continuation sheet shall be attached.

It is highly desirable that the abstract of classified reports be unclassified. Each paragraph of the abstract shall end with an indication of the military security classification of the information in the paragraph, represented as (TS), (S), (C), or (U).

There is no limitation on the length of the abstract. However, the suggested length is from 150 to 225 words.

14. **KEY WORDS:** Key words are technically meaningful terms or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location, may be used as key words but will be followed by an indication of technical content. The assignment of links, rules, and weights is optional.